Head of clinical development for virology, Gilead Sciences
Appears in 1 story
Leads the lenacapavir portfolio that anchors Bixlenvo
Roughly 5% of Americans living with HIV take their antiretrovirals as several pills a day, because resistance, side effects, or other medications rule out standard single tablets. On Thursday the FDA approved a pill built for that group.
Updated Aug 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
